Document is current
Any future updates will be listed below
-
Authors
Alsafadi, Samar http://orcid.org/0000-0002-0060-1346
Dayot, Stephane
Tarin, Malcy
Houy, Alexandre http://orcid.org/0000-0001-6267-2353
Bellanger, Dorine
Cornella, Michele
Wassef, Michel
Waterfall, Joshua J. http://orcid.org/0000-0002-3762-5050
Lehnert, Erik
Roman-Roman, Sergio
Stern, Marc-Henri http://orcid.org/0000-0002-8100-2272
Popova, Tatiana
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (667787, 667787, 667787)
Ligue Contre le Cancer (Labellisation)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (HHSN261201400008C)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (HHSN261201500003I)
- License Information
-
More Information
Article History
Received: 18 May 2020
Revised: 30 September 2020
Accepted: 1 October 2020
First Online: 14 October 2020
Compliance with ethical standards
:
: AH and MHS are inventors of a patent pending related to <i>SUGP1</i> and <i>SF3B1</i> mutations effects. EL was employed by Seven Bridges Genomics. Other authors declare no conflict of interest.
